Is Revolve Group Stock a Buy, Sell or Hold?
Recently, Revolve Group (NYSE:RVLV) management delivered some fairly positive business…
Sell
29
LEGN Quote, Financials, Valuation and Earnings
Last price:
$31.99
Seasonality move
:
24.4%
Day range:
$31.23 - $32.56
52-week range:
$29.27 - $60.87
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
9.33x
P/B ratio:
5.65x
Volume:
1.6M
Avg. volume:
1.2M
1-year change:
-41.83%
Market cap:
$5.9B
Revenue:
$627.2M
EPS (TTM):
-$0.98
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LEGN
Legend Biotech
|
$191.5M | -$0.27 | 104.21% | -8.33% | $78.01 |
|
AGEN
Agenus
|
$26.4M | -$1.60 | -5.82% | -97.37% | $7.00 |
|
ALNY
Alnylam Pharmaceuticals
|
$586.2M | -$0.34 | 20.07% | -15.81% | $313.97 |
|
GILD
Gilead Sciences
|
$6.8B | $1.75 | 0.04% | 50.49% | $112.46 |
|
JNJ
Johnson & Johnson
|
$21.6B | $2.58 | 0.55% | 38.85% | $169.87 |
|
SLNO
Soleno Therapeutics
|
-- | -- | -- | -- | $102.13 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LEGN
Legend Biotech
|
$32.00 | $78.01 | $5.9B | -- | $0.00 | 0% | 9.33x |
|
AGEN
Agenus
|
$1.70 | $7.00 | $43M | -- | $0.00 | 0% | 0.27x |
|
ALNY
Alnylam Pharmaceuticals
|
$237.77 | $313.97 | $30.8B | -- | $0.00 | 0% | 13.50x |
|
GILD
Gilead Sciences
|
$103.63 | $112.46 | $129.1B | 280.08x | $0.79 | 2.99% | 4.53x |
|
JNJ
Johnson & Johnson
|
$151.73 | $169.87 | $365.6B | 26.21x | $1.24 | 3.27% | 4.15x |
|
SLNO
Soleno Therapeutics
|
$67.23 | $102.13 | $3.1B | -- | $0.00 | 0% | 3,450.85x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LEGN
Legend Biotech
|
22.45% | 1.522 | 5.04% | 4.49x |
|
AGEN
Agenus
|
-11.31% | 3.589 | 39.16% | 0.18x |
|
ALNY
Alnylam Pharmaceuticals
|
93.86% | 1.604 | 3.37% | 2.61x |
|
GILD
Gilead Sciences
|
58.02% | 0.600 | 23.22% | 1.33x |
|
JNJ
Johnson & Johnson
|
33.88% | 0.428 | 10.52% | 0.86x |
|
SLNO
Soleno Therapeutics
|
-- | -2.069 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LEGN
Legend Biotech
|
$112.6M | -$74.4M | -12.31% | -15.44% | 24.48% | -$84.5M |
|
AGEN
Agenus
|
-$7.1M | -$28M | -- | -- | -97.33% | -$28.7M |
|
ALNY
Alnylam Pharmaceuticals
|
$490.3M | -$105.2M | -29.16% | -- | -26.13% | -$103.8M |
|
GILD
Gilead Sciences
|
$6B | $2.4B | 1.09% | 2.5% | 31.92% | $2.8B |
|
JNJ
Johnson & Johnson
|
$15.4B | $3.8B | 13.3% | 19.98% | 17.87% | $4.8B |
|
SLNO
Soleno Therapeutics
|
-- | -$58.8M | -- | -- | -- | -$24M |
Legend Biotech vs. Competitors
-
Which has Higher Returns LEGN or AGEN?
Agenus has a net margin of 14.09% compared to Legend Biotech's net margin of -170.88%. Legend Biotech's return on equity of -15.44% beat Agenus's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LEGNLegend Biotech60.37% $0.14 $1.3B AGENAgenus-26.29% -$1.94 -$273.3M -
What do Analysts Say About LEGN or AGEN?
Legend Biotech has a consensus price target of $78.01, signalling upside risk potential of 143.79%. On the other hand Agenus has an analysts' consensus of $7.00 which suggests that it could grow by 311.77%. Given that Agenus has higher upside potential than Legend Biotech, analysts believe Agenus is more attractive than Legend Biotech.
Company Buy Ratings Hold Ratings Sell Ratings LEGNLegend Biotech11 2 0 AGENAgenus1 4 0 -
Is LEGN or AGEN More Risky?
Legend Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Agenus has a beta of 1.578, suggesting its more volatile than the S&P 500 by 57.761%.
-
Which is a Better Dividend Stock LEGN or AGEN?
Legend Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Legend Biotech pays -- of its earnings as a dividend. Agenus pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LEGN or AGEN?
Legend Biotech quarterly revenues are $186.5M, which are larger than Agenus quarterly revenues of $26.8M. Legend Biotech's net income of $26.3M is higher than Agenus's net income of -$45.9M. Notably, Legend Biotech's price-to-earnings ratio is -- while Agenus's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Legend Biotech is 9.33x versus 0.27x for Agenus. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LEGNLegend Biotech9.33x -- $186.5M $26.3M AGENAgenus0.27x -- $26.8M -$45.9M
-
Which has Higher Returns LEGN or ALNY?
Alnylam Pharmaceuticals has a net margin of 14.09% compared to Legend Biotech's net margin of -14.12%. Legend Biotech's return on equity of -15.44% beat Alnylam Pharmaceuticals's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LEGNLegend Biotech60.37% $0.14 $1.3B ALNYAlnylam Pharmaceuticals82.67% -$0.65 $1.1B -
What do Analysts Say About LEGN or ALNY?
Legend Biotech has a consensus price target of $78.01, signalling upside risk potential of 143.79%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $313.97 which suggests that it could grow by 32.05%. Given that Legend Biotech has higher upside potential than Alnylam Pharmaceuticals, analysts believe Legend Biotech is more attractive than Alnylam Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings LEGNLegend Biotech11 2 0 ALNYAlnylam Pharmaceuticals12 8 1 -
Is LEGN or ALNY More Risky?
Legend Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.300, suggesting its less volatile than the S&P 500 by 70.047%.
-
Which is a Better Dividend Stock LEGN or ALNY?
Legend Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Legend Biotech pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LEGN or ALNY?
Legend Biotech quarterly revenues are $186.5M, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $593.2M. Legend Biotech's net income of $26.3M is higher than Alnylam Pharmaceuticals's net income of -$83.8M. Notably, Legend Biotech's price-to-earnings ratio is -- while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Legend Biotech is 9.33x versus 13.50x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LEGNLegend Biotech9.33x -- $186.5M $26.3M ALNYAlnylam Pharmaceuticals13.50x -- $593.2M -$83.8M
-
Which has Higher Returns LEGN or GILD?
Gilead Sciences has a net margin of 14.09% compared to Legend Biotech's net margin of 23.56%. Legend Biotech's return on equity of -15.44% beat Gilead Sciences's return on equity of 2.5%.
Company Gross Margin Earnings Per Share Invested Capital LEGNLegend Biotech60.37% $0.14 $1.3B GILDGilead Sciences79.11% $1.42 $46B -
What do Analysts Say About LEGN or GILD?
Legend Biotech has a consensus price target of $78.01, signalling upside risk potential of 143.79%. On the other hand Gilead Sciences has an analysts' consensus of $112.46 which suggests that it could grow by 8.52%. Given that Legend Biotech has higher upside potential than Gilead Sciences, analysts believe Legend Biotech is more attractive than Gilead Sciences.
Company Buy Ratings Hold Ratings Sell Ratings LEGNLegend Biotech11 2 0 GILDGilead Sciences14 12 0 -
Is LEGN or GILD More Risky?
Legend Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.322, suggesting its less volatile than the S&P 500 by 67.831%.
-
Which is a Better Dividend Stock LEGN or GILD?
Legend Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 2.99% to investors and pays a quarterly dividend of $0.79 per share. Legend Biotech pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.
-
Which has Better Financial Ratios LEGN or GILD?
Legend Biotech quarterly revenues are $186.5M, which are smaller than Gilead Sciences quarterly revenues of $7.6B. Legend Biotech's net income of $26.3M is lower than Gilead Sciences's net income of $1.8B. Notably, Legend Biotech's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 280.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Legend Biotech is 9.33x versus 4.53x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LEGNLegend Biotech9.33x -- $186.5M $26.3M GILDGilead Sciences4.53x 280.08x $7.6B $1.8B
-
Which has Higher Returns LEGN or JNJ?
Johnson & Johnson has a net margin of 14.09% compared to Legend Biotech's net margin of 15.24%. Legend Biotech's return on equity of -15.44% beat Johnson & Johnson's return on equity of 19.98%.
Company Gross Margin Earnings Per Share Invested Capital LEGNLegend Biotech60.37% $0.14 $1.3B JNJJohnson & Johnson68.35% $1.41 $108.1B -
What do Analysts Say About LEGN or JNJ?
Legend Biotech has a consensus price target of $78.01, signalling upside risk potential of 143.79%. On the other hand Johnson & Johnson has an analysts' consensus of $169.87 which suggests that it could grow by 11.96%. Given that Legend Biotech has higher upside potential than Johnson & Johnson, analysts believe Legend Biotech is more attractive than Johnson & Johnson.
Company Buy Ratings Hold Ratings Sell Ratings LEGNLegend Biotech11 2 0 JNJJohnson & Johnson7 11 0 -
Is LEGN or JNJ More Risky?
Legend Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.995%.
-
Which is a Better Dividend Stock LEGN or JNJ?
Legend Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.27% to investors and pays a quarterly dividend of $1.24 per share. Legend Biotech pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LEGN or JNJ?
Legend Biotech quarterly revenues are $186.5M, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Legend Biotech's net income of $26.3M is lower than Johnson & Johnson's net income of $3.4B. Notably, Legend Biotech's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 26.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Legend Biotech is 9.33x versus 4.15x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LEGNLegend Biotech9.33x -- $186.5M $26.3M JNJJohnson & Johnson4.15x 26.21x $22.5B $3.4B
-
Which has Higher Returns LEGN or SLNO?
Soleno Therapeutics has a net margin of 14.09% compared to Legend Biotech's net margin of --. Legend Biotech's return on equity of -15.44% beat Soleno Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LEGNLegend Biotech60.37% $0.14 $1.3B SLNOSoleno Therapeutics-- -$1.27 -- -
What do Analysts Say About LEGN or SLNO?
Legend Biotech has a consensus price target of $78.01, signalling upside risk potential of 143.79%. On the other hand Soleno Therapeutics has an analysts' consensus of $102.13 which suggests that it could grow by 51.9%. Given that Legend Biotech has higher upside potential than Soleno Therapeutics, analysts believe Legend Biotech is more attractive than Soleno Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings LEGNLegend Biotech11 2 0 SLNOSoleno Therapeutics5 0 0 -
Is LEGN or SLNO More Risky?
Legend Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Soleno Therapeutics has a beta of -2.285, suggesting its less volatile than the S&P 500 by 328.466%.
-
Which is a Better Dividend Stock LEGN or SLNO?
Legend Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Soleno Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Legend Biotech pays -- of its earnings as a dividend. Soleno Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LEGN or SLNO?
Legend Biotech quarterly revenues are $186.5M, which are larger than Soleno Therapeutics quarterly revenues of --. Legend Biotech's net income of $26.3M is higher than Soleno Therapeutics's net income of -$56M. Notably, Legend Biotech's price-to-earnings ratio is -- while Soleno Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Legend Biotech is 9.33x versus 3,450.85x for Soleno Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LEGNLegend Biotech9.33x -- $186.5M $26.3M SLNOSoleno Therapeutics3,450.85x -- -- -$56M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Bloom Energy Stock a Buy, Sell or Hold?
While already interesting as the world moves toward greener energy…
What Do Tesla Delivery Numbers Mean for Tesla Stock?
Tesla (NASDAQ:TSLA) released Q1 delivery numbers, showing a substantial slowdown…
Stock Ideas
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
50
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
52
RGC alert for Apr 12
Regencell Bioscience Holdings [RGC] is up 29.14% over the past day.
Buy
52
SLP alert for Apr 12
Simulations Plus [SLP] is up 26.73% over the past day.
Buy
89
GDXU alert for Apr 12
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 15.9% over the past day.
